OxThera Initiates Extension Part of a Phase 3 Study of Oxabact in Primary Hyperoxaluria (Cision PR Newswire)

OxThera Initiates Extension Part of a Phase 3 Study of Oxabact in Primary Hyperoxaluria

UF startup OxThera AB, a privately-held Stockholm-based biopharmaceutical company dedicated to improving the lives of people living with Primary Hyperoxaluria, announced that the first patients in a Phase 3 study of Oxabact® have completed the study and transitioned to an open-label extension part. All clinics participating in the study will continue to treat patients in the extension part for another two years. Topline results from the Phase 3 study are expected in the first quarter of 2021.

Primary Hyperoxaluria is a rare autosomal recessive disorder leading to markedly elevated levels of endogenous oxalate in plasma and urine. High levels of oxalate cause kidney damage, including crystallization of oxalate in tissues and in the kidney. If left untreated, the disease can cause kidney failure and premature death.

Learn more about OxThera Initiates Extension Part of a Phase 3 Study of Oxabact in Primary Hyperoxaluria.
X